Literature DB >> 8734823

A program for eradication of hepatitis B from Taiwan by a 10-year, four-dose vaccination program.

D S Chen1, H M Hsu, C L Bennett, T S Pajeau, B Blumberg, P Y Chang, K Nishioka, A Huang, J L Sung.   

Abstract

Approximately 15 percent of the Taiwanese population are chronic carriers of hepatitis B virus (HBV), among the highest rates in Asia. In July 1984, the Taiwanese government initiated a nationwide HBV-vaccination program. The program began with educational efforts and voluntary prenatal screening for HBsAg. Infants of HBsAg-carrier mothers received a four-dose regimen of hepatitis B vaccine. Those born to highly infectious mothers also received a dose of hepatitis-B immune globulin within 24 hours after birth. Seroepidemiologic studies were conducted using a random sample of infants. Serum samples were collected at 18, 24, 36, and 48 months and analyzed via radioimmunoassay for HBsAg, anti-HBs, and anti-HBc. Infants of highly infectious mothers had HBsAg positivity rates of 14.2 percent (vaccine plus HBIG) and 19.7 percent (vaccine only) when on schedule, and 17.0 percent when off schedule. Infants of moderately infectious mothers had an HBsAg positivity rate of 3.0 percent when on schedule and 6.4 percent when off schedule. These low positivity rates persisted throughout the 48-month follow-up period. This represents a dramatic improvement upon the 40 to 96 percent vertical transmission rate seen before the program implementation. This program demonstrates that mass immunoprophylaxis for HBV is feasible, and provides practical strategies for other Asian countries.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8734823     DOI: 10.1007/bf00052935

Source DB:  PubMed          Journal:  Cancer Causes Control        ISSN: 0957-5243            Impact factor:   2.506


  8 in total

1.  A "NEW" ANTIGEN IN LEUKEMIA SERA.

Authors:  B S BLUMBERG; H J ALTER; S VISNICH
Journal:  JAMA       Date:  1965-02-15       Impact factor: 56.272

2.  Vertical transmission of hepatitis B antigen in Taiwan.

Authors:  C E Stevens; R P Beasley; J Tsui; W C Lee
Journal:  N Engl J Med       Date:  1975-04-10       Impact factor: 91.245

3.  Hepatitis B virus infection and chronic liver disease in Taiwan.

Authors:  D S Chen; J L Sung
Journal:  Acta Hepatogastroenterol (Stuttg)       Date:  1978-12

4.  Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan.

Authors:  R P Beasley; L Y Hwang; C C Lin; C S Chien
Journal:  Lancet       Date:  1981-11-21       Impact factor: 79.321

5.  From hepatitis to hepatoma: lessons from type B viral hepatitis.

Authors:  D S Chen
Journal:  Science       Date:  1993-10-15       Impact factor: 47.728

6.  Combined passive and active immunization for preventing perinatal transmission of hepatitis B virus carrier state.

Authors:  H Tada; M Yanagida; J Mishina; T Fujii; K Baba; S Ishikawa; S Aihara; F Tsuda; Y Miyakawa; M Mayumi
Journal:  Pediatrics       Date:  1982-10       Impact factor: 7.124

7.  A mass vaccination program in Taiwan against hepatitis B virus infection in infants of hepatitis B surface antigen-carrier mothers.

Authors:  D S Chen; N H Hsu; J L Sung; T C Hsu; S T Hsu; Y T Kuo; K J Lo; Y T Shih
Journal:  JAMA       Date:  1987-05-15       Impact factor: 56.272

8.  Efficacy of a mass hepatitis B vaccination program in Taiwan. Studies on 3464 infants of hepatitis B surface antigen-carrier mothers.

Authors:  H M Hsu; D S Chen; C H Chuang; J C Lu; D M Jwo; C C Lee; H C Lu; S H Cheng; Y F Wang; C Y Wang
Journal:  JAMA       Date:  1988-10-21       Impact factor: 56.272

  8 in total
  3 in total

1.  CpG DNA can induce strong Th1 humoral and cell-mediated immune responses against hepatitis B surface antigen in young mice.

Authors:  C L Brazolot Millan; R Weeratna; A M Krieg; C A Siegrist; H L Davis
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-22       Impact factor: 11.205

Review 2.  Hepatitis B Virus Reactivation: Risk Factors and Current Management Strategies.

Authors:  Danielle J Smalls; Reagan E Kiger; LeAnn B Norris; Charles L Bennett; Bryan L Love
Journal:  Pharmacotherapy       Date:  2019-11-03       Impact factor: 4.705

3.  Essential components in developing public policy to control viral hepatitis: lessons from Taiwan.

Authors:  Jack Wallace; Marian Pitts; Stephen Locarnini; Jeanne Ellard; Marina Carman; Ding-Shinn Chen
Journal:  Hepatol Int       Date:  2015-09-04       Impact factor: 6.047

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.